INS and fatty liver disease: Additionally, in vivo, class I HDAC inhibition resulted in a remarkable decrease in body weight, while both global and class I HDAC inhibition led to a decrease in fasting glycemia, circulating insulin, and triglycerides, as well as improvements in glucose tolerance, insulin resistance and hepatic steatosis in obese diabetic db/db mice.